Acquisition would bolster its presence in the plasma therapeutics segment.
CSL plans to acquire Talecris Biotherapeutics for $3.1 billion in cash to expand its share of the plasma therapeutics market. The amount as per the definitive merger agreement includes net debt, which as of June 30 was approximately $1.2 billion.
Under a separate plasma-supply agreement, CSL says that it will provide Talecris with a significant amount of plasma until 2013. This will help Talecris assure an uninterrupted flow of products to its customers, distributors, and patients and will also facilitate Talecris’ efforts to build its plasma-supply platform in a measured, quality-compliant manner, the firms note.
If the necessary approvals are not obtained within a year, either CSL or Talecris has the right to terminate the transaction. If the takeover is sanctioned, CSL would gain a broad portfolio in the plasma-derived therapeutics and expanded manufacturing capabilities.